by Adam Smartt | Oct 5, 2020 | Established Investigator Award
Description: Over the past decade, harnessing the power of a patient’s own immune system for the treatment of cancer has been a major medical breakthrough. By using drugs to block inhibitory signals on immune cells, these medicines help “release the... by Adam Smartt | Oct 5, 2020 | Established Investigator Award
Description: The majority of cancer patients do not yet benefit from immunotherapy, including from immune checkpoint therapies that invigorate the patients’ own immune systems to fight their tumors. In many cases the underlying reason is that tumors are not... by Adam Smartt | Oct 5, 2020 | Established Investigator Award
Description: Melanoma is one of the fastest growing malignancies and accounts for 5.5% of all new cancer cases in the United States. Treatment options and prognosis of melanoma patients depend on the risk stratification. Survival is excellent in low risk groups and... by Adam Smartt | Sep 24, 2019 | Established Investigator Award
Principal Investigator: J. William Harbour, MD University of Miami Uveal melanoma (UM) is a highly aggressive eye cancer that leads to metastatic death in up to half of patients, with no measurable improvement in survival over the past half century. As such, there is...
SEARCH
Recent Comments